Blog
Etigilimab Biosimilar: Advancing TIGIT Inhibition in Cancer Immunotherapy
Etigilimab is a monoclonal antibody targeting TIGIT (T-cell immunoglobulin and ITIM domain), an immune checkpoint receptor that suppresses T-cell activity in tumors. By blocking TIGIT, Et
…
10th Dec 2024